Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 24, 2026.

Therapeutic Potential of Volatile Terpenes and Terpenoids from Forests for Inflammatory Diseases

Taejoon Kim, Bokyeong Song, Kyoung Sang Cho and 1 more

International Journal of Molecular Sciences · 2020 · Review · CC BY

doi:10.3390/ijms21062187

Abstract

Forest trees are a major source of biogenic volatile organic compounds (BVOCs). Terpenes and terpenoids are known as the main BVOCs of forest aerosols. These compounds have been shown to display a broad range of biological activities in various human disease models, thus implying that forest aerosols containing these compounds may be related to beneficial effects of forest bathing. In this review, we surveyed studies analyzing BVOCs and selected the most abundant 23 terpenes and terpenoids emitted in forested areas of the Northern Hemisphere, which were reported to display anti-inflammatory activities. We categorized anti-inflammatory processes related to the functions of these compounds into six groups and summarized their molecular mechanisms of action. Finally, among the major 23 compounds, we examined the therapeutic potentials of 12 compounds known to be effective against respiratory inflammation, atopic dermatitis, arthritis, and neuroinflammation among various inflammatory diseases. In conclusion, the updated studies support the beneficial effects of forest aerosols and propose their potential use as chemopreventive and therapeutic agents for treating various inflammatory diseases.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

1.1. Terpenes and Terpenoids

Trees in forests are a major source of a broad range of biogenic volatile organic compounds (BVOCs) that constitute a large and diverse class of plant secondary metabolites. The main role of these compounds is to protect plants from herbivores and pathogenic microorganisms by displaying direct toxicity, repelling herbivores, or attracting herbivores’ enemies. It was reported that a given plant species emits a mixture of BVOCs, which can be highly complex, containing up to 200 different compounds.

The majority of BVOCs emitted by plants are terpenes and terpenoids. These compounds represent one of the largest groups of plant secondary metabolites, with approximately 55,000 different structures. The structure of terpenes is based on the linkage of isoprene units (C5H8) such as dimethylallyl pyrophosphate and isopentenyl pyrophosphate. These two C5 building blocks generate various terpene compounds by head-to-tail condensation. Depending on the number of linked isoprene units, the resulting terpenes are classified into hemi-, mono-, sesqui-, di-, sester-, tri-, sesquar-, tetra-, and polyterpenes (C5, C10, C15, C20, C25, C30, C35, C40, and longer chains of C5, respectively). In contrast to terpenes that are hydrocarbons, terpenes containing additional functional groups, usually oxygen-containing are called terpenoids. As deduced from their various structures, terpenes and terpenoids have been reported to exhibit diverse biological activities. Among them, the beneficial effects of terpene and terpenoid compounds on human health have been attracting the attention of numerous researchers, and their roles in various human disease processes, such as inflammatory diseases, tumorigenesis, and neurodegeneration, have been studied using cell and animal models for many decades, suggesting terpenes and terpenoids as potential chemopreventive and therapeutic agents for various diseases. In recent years, small subgroups of novel terpenes and terpenoids have been isolated or synthesized, providing more potentially chemotherapeutic terpene compounds for clinical trials.

The terpenes and terpenoids in BVOCs can be classified into four groups: isoprenes, monoterpenes, sesquiterpenes, and oxygenated hydrocarbons. In forested areas, monoterpenes and isoprenes are the major BVOCs that contribute to substantial emission levels to the atmosphere. Monoterpenes are mostly emitted by coniferous species, whereas broad-leaved trees mainly emit isoprenes. In contrast to the various beneficial effects of terpene compounds in human disease models, isoprenes have been recently shown to act as signaling molecules important for stress responses and growth in plants; however, little is known about their positive effects on human health. Moreover, substantial emission of isoprene increases the production of ozone and smog in the presence of nitrogen oxides, due to its reactivity with hydroxyl radicals, adversely affecting the environment.

Various terpenes and terpenoids, mainly monoterpenes and sesquiterpenes, can be continuously emitted from specialized storage organs in leaves, stems, and trunks of trees, while others are synthesized de novo after invasion of a pathogen to defend the plants. Due to medicinal effects of terpenes and terpenoids, forest bathing has been suggested to exhibit positive influences on human health via showering of forest aerosols containing the compounds, in addition to its physical relaxation effect. This review summarizes the anti-inflammatory effects of 23 selected BVOCs from forests: 13 monoterpenes, 7 oxygenated monoterpenes, 1 monoterpene derivative, and 2 sesquiterpenes (Table 1). We surveyed the studies analyzing BVOCs emitted in various mixed as well as pure forests in North America (the United States), Europe (Estonia, France, and Turkey), or Asia (South Korea). These forest areas are located between latitudes 33 and 58 degrees in the Northern Hemisphere, mostly in the temperate zone that is also called as the mid-latitudes. These compounds were chosen because they are not only the major terpenes and terpenoids emitted in the forests, but also because as single compounds have beneficial effects on inflammatory processes with known molecular mechanisms.

1.2. Inflammation

Inflammation is a protective response of the host to infections and tissue damages, mediated by the activation of various immune cells. However, deregulated inflammatory responses can result in acute and chronic inflammatory diseases causing excessive or long-lasting tissue damages. Macrophages play a central role in many different immune-pathological phenomena during inflammation, including overproduction of pro-inflammatory cytokines and inflammatory mediators, such as interleukin IL-1β, IL-6, tumor necrosis factor-alpha (TNF-α), and nitric oxide (NO) synthesized by inducible NO synthase (iNOS), and prostaglandin E2 (PGE-2) synthesized by cyclooxygenase-2 (COX-2). Nuclear factor-κB (NF-κB) is a central transcription factor that regulates expression of pro-inflammatory genes during inflammation.

In the canonical pathway triggered by Toll-like receptors (TLRs) and proinflammatory cytokines such as TNF-α and IL-1, the activated NF-κB translocates to the nucleus and regulates the expression of the pro-inflammatory genes. Additionally, the pro-inflammatory mediators activate the signal transduction pathways of the core mitogen-activated protein kinases [MAPKs: extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38], which, in turn, control various cellular processes by regulating downstream protein kinases and transcription factors.

Several cellular processes including oxidative stress and autophagy also play an important role in inflammation. Reactive oxygen species (ROS), produced from several sources including the mitochondria, mediates the increase in leukocyte migration and junctional permeability via various signaling mechanisms. In addition, a recent study showed that ROS regulates IL-1β release by directly interfering with NF-κB signaling. Autophagy, a recycling process of cytosolic materials, is also closely related to inflammation. By influencing the development, homeostasis, and survival of inflammatory cells and by affecting the generation of cytokines, autophagy plays a critical role in inflammation. In addition to the above processes, other pathways can be involved in inflammation progression, such as the endoplasmic reticulum (ER) stress and microRNA regulation. Since these cellular processes hold such an important role in inflammation, their regulators could also modulate inflammation.

2. Anti-Inflammatory Effects of Volatile Terpene and Terpenoids in Forests

Studies in recent decades have demonstrated that terpenes and terpenoids ameliorate various symptoms caused by inflammation via inhibiting various steps of inflammatory processes. In this section, we categorize the anti-inflammatory activities of 23 compounds, which are the major terpenes and terpenoids emitted in the forests, into six groups and describe studies that revealed the mechanisms of their anti-inflammatory activities at the molecular level (summarized in Table 2).

2.1. Regulation of Pro-Inflammatory Mediators

As shown in Table 2, the majority of anti-inflammatory functions of terpenes and terpenoids have been shown to be mediated by a decrease in the levels of pro-inflammatory mediators, such as NO, interleukins, TNF-α, and PGE2. Several in vitro studies have used these pro-inflammatory mediators as biomarkers for evaluating the anti-inflammatory activity of terpenes. For example, when the RAW 264.7 cells, murine macrophages, were stimulated by lipopolysaccharide (LPS), the levels of pro-inflammatory mediators were significantly increased. Pre-treatment with several terpenes including d-limonene, terpinolene, linalool, α-terpineol, α-phellandrene, and γ-terpinene, reduced LPS-induced pro-inflammatory mediator production in in vitro cultured RAW 264.7 cells. In cultured chondrocytes, an in vitro model of arthritis-related inflammation, d-limonene and myrcene decreased NO and iNOS levels, while bornyl acetate elevated the expression of IL-11, which inhibits IL-1β-mediated up-regulation of IL-6, IL-8, matrix metallopeptidases (MMP)-1, and MMP-13.

The anti-inflammatory activity of terpenes is also evaluated using various in vivo inflammatory disease models. For example, α-phellandrene, 1,8-cineole, borneol, and terpinen-4-ol inhibited the production of pro-inflammatory mediators induced by treatment with inflammatory substances, such as LPS and carrageenan, in lung injury models. Furthermore, 1,8-cineole reduced the levels of various cytokines, such as IL-1β, IL-4, IL-6, IL-13 and IL-17A, and TNF-α in bronchoalveolar lavage fluid of asthma models sensitized with ovalbumin (OVA) or house dust mite and short-term cigarette smoke exposure of mice. The inhibitory effect of 1,8-cineole on the levels of PGE2 has been also shown in an ex vivo study using blood monocytes of patients with bronchial asthma. Two other terpenes, linalool and humulene, also reduced the production of pro-inflammatory mediators in an asthma mouse model sensitized with OVA. In addition, the anti-inflammatory effects of some terpenes have also been tested in experimental colitis models. For example, borneol, terpinen-4-ol, and β-caryophyllene reduced the levels of IL-1β, IL-6, NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome, in experimental colitis models induced by 2,4,6-trinitrobenzene sulfonic acid (TNBS) or dextran sulfate sodium (DSS).

Based on their anti-inflammatory properties, researchers have been testing terpenes in vitro as well as in vivo to examine whether they also inhibit neuroinflammation. β-Caryophyllene has been reported to reduce inflammatory activity of BV2 microglia cells under hypoxia or after treatment with amyloid β (Aβ) peptide, while 1,8-cineole lowered the levels of NO and proinflammatory cytokines in Aβ-treated PC12 cells. On the other hand, several studies have shown the effects of terpenes on the production of pro-inflammatory mediators during neuroinflammation in in vivo models. For example, d-limonene decreased NO levels in Aβ42-expressing fly heads, and linalool reduced the levels of the pro-inflammatory markers p38 MAPK, NOS2, COX2 and IL-1β in the brain of a triple transgenic mouse model of Alzheimer’s disease (3xTg-AD). Moreover, borneol attenuated the elevation of NO, the increase in iNOS enzymatic activity and the upregulation of iNOS expression in an ischemic model of oxygen-glucose deprivation followed by reperfusion.

2.2. Regulation of Transcription Factors Involved in Inflammatory Responses

As NF-κB is the main transcriptional factor that regulates the expression of pro-inflammatory mediators, it is frequently considered a target of anti-inflammatory molecules. Consistently, a number of studies have shown that the inhibitory effects of several terpenes on the production pro-inflammatory mediators is mediated by the down-regulation of NF-κB expression or activity (Table 2). However, most studies have only shown that the translocation of NF-κB into the nucleus, the phosphorylation of I-κB and NF-κB, and the NF-κB expression levels were reduced by terpene treatment. These studies did not show that terpene-induced reduction of NF-κB activity was a direct cause of inhibition of expression of pro-inflammatory mediators. Furthermore, there was little mention of how terpenes inhibit the activity of NF-κB.

In addition, nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor that is involved in cellular responses to oxidative damage and inflammation, is also regulated by several terpenes. Previous studies have shown that α-pinene, β-caryophyllene, borneol, 1,8-cineole, and linalool up-regulated Nrf2 activity to protect cells from oxidative damage. However, in the case of terpenes other than linalool, it is unclear whether the increased Nrf2 activity by these terpenes is associated with their anti-inflammatory action. In LPS-stimulated BV2 microglia cells, linalool-induced nuclear translocation of Nrf2, and the anti-inflammatory effect of linalool was attenuated by transfection with Nrf2 siRNA.

2.3. Signal Transduction and Direct Targets of Terpene Compounds

Inflammatory responses are regulated by a variety of signaling pathways; however, surprisingly, few studies have examined the effects of terpenes on signal transduction. Mitogen-activated protein kinase MAPK signal transduction pathways, such as ERK, JNK, and p38, play an important role in inflammatory responses, and a variety of terpenes have been shown to inhibit these signaling pathways and to exert anti-inflammatory activities in various experimental models. In addition, a recent study has reported that borneol induced the activation of M2 macrophages in a STAT3-dependent manner in a DSS-induced colitis model. Unfortunately, little is known about how terpenes affect these signaling systems.

Interestingly, several terpenes, including borneol, camphor, 1,8-cineole, limonene, and linalool activate transient receptor potential vanilloids (TRPVs), a family of transient receptor potential cation channels. As TRPVs have been strongly implicated in inflammatory responses, these channels are likely to mediate the anti-inflammatory action of some terpenes. However, there are conflicting data on the role of TRPV channels in the inflammatory response, and to date, there is not much experimental evidence on their role in the anti-inflammatory action of terpenes. Meanwhile, β-caryophyllene is known as a functional agonist of cannabinoid type 2 receptor (CB(2)R). CB(2)R is the peripheral receptor for cannabinoids, which is mainly expressed in immune tissues and has been shown to modulate immune cell functions. In a DSS-induced colitis model and a cisplatin-induced nephropathy model, CB(2)R mediated the anti-inflammatory activities of β-caryophyllene. Similarly, the inhibitory effects of β-caryophyllene on the activation of NF-κB and the secretion of inflammatory cytokines were abolished by CB(2)R RNA interference in cultured microglia under hypoxia, suggesting that CB(2)R mediates anti-inflammatory responses induced by β-caryophyllene.

2.4. Function of Terpene Compounds against Oxidative Stress

Oxidative stress results from an imbalance between the production of ROS and their elimination by protective mechanisms. The excessive production of ROS causes tissue injury that may lead to the inflammatory process. ROS generation occurs in two ways: it can be naturally produced within the cells and plays roles in the regulation of cell homeostasis and functions or it can be produced during cell respiration in mitochondrial oxidative metabolism. The main targets of oxidative stress are proteins, lipids, and DNA/RNA; modifications in these molecules may increase the chance of mutagenesis, as well as irreversible damage to cells, resulting in cell death by necrotic and apoptotic processes. Terpene compounds may reduce the catalytic activity of enzymes involved in ROS generation, or may protect against oxidative damage through several mechanisms of antioxidant activity including scavenging a wide range of ROS and capacity for metal ion chelation.

Many studies have demonstrated antioxidative stress activities of volatile terpenes and terpenoids in vitro. d-Limonene is a monoterpene with powerful antioxidative properties. Apoptosis of human lens epithelial cells has been suggested as a cause of cataract. The in vitro study by Bai et al. showed that d-limonene can effectively protect the lens epithelial cells from apoptosis caused by H2O2-induced oxidative stress by inhibiting ROS generation, caspase-3/caspase-9 activation, p38 MAPK phosphorylation, and by increasing the Bcl-2/Bax ratio, thereby suggesting its beneficial use for treating cataracts. Furthermore, d-limonene not only induced proliferation of normal lymphocytes by decreasing H2O2 levels via increased antioxidant enzymatic activities, but also protected the cells from the oxidative stress induced by exogenous H2O2, indicating the pharmacological potential of limonene on normal lymphocytes in various diseases related to oxidative stress. Similarly, myrcene, a well-known natural anti-photoaging product, decreased the production of ROS, MMP-1, MMP-3, and IL-6, and increased transforming growth factor type 1 (TGF 1) and type I procollagen secretion in UVB-irradiated human dermal fibroblasts. Furthermore, myrcene treatment dramatically reduced the phosphorylation of various MAPK-related signaling molecules, suggesting its potential application in the skincare industry owing to its protective effect on photoaging. Terpinolene and α-phellandrene have also been shown to attenuate inflammation and oxidative stress in vitro by significantly inhibiting NO and superoxide production in a macrophage cell-culture-based assay. In another in vitro experiment to assess antioxidant capacities, four monoterpenes, linalool, linalyl acetate, α-terpinene, and γ-terpinene, were found to scavenge peroxyl radicals, strong oxidant nitrogen radicals, weak oxidant nitrogen radicals, and lipidic peroxyl radicals, as well as to chelate oxidant metal ions.

In addition to their in vitro functions, antioxidative stress activities of volatile terpenes and terpenoids have also been demonstrated in vivo. Camphene, another strong antioxidant, has been assessed for its antioxidant potential using tert-butyl hydroperoxide (t-BHP)-stressed rat alveolar macrophages. Camphene increased the cell viability and glutathione (GSH) content and restored the mitochondrial membrane potential, but inhibited NO release and ROS generation. Compared to other terpenes, camphene has also been found to have high scavenging activities against different free radicals generated in vitro, suggesting its possible therapeutic role in various inflammatory diseases.

Antioxidant effects of volatile terpenes and terpenoids have also been demonstrated in brain cells in vitro as well as in vivo. α-Pinene and 1,8-cineole have shown their potential in vitro antioxidant activities against H2O2-induced oxidative stress in the astrocytic U373-MG cell line by inhibiting ROS production and lipid peroxidation as well as by increasing the endogenous antioxidant status, suggesting the two compounds as regulators of the cellular redox balance in astrocytes. Similarly, both sesquiterpenes, humulene and β-caryophyllene, have been reported to have protective activity on cultured primary brain astrocytes against H2O2-induced cell death, possibly due to their accumulation in the cytosol. β-Caryophyllene alone has shown to reduce the rate of ROS production and the associated respiratory activity albeit in an arthritic rat model. In addition to those effects in astrocytic cells, another monoterpene linalool reduced cell death of immortalized neuronal HT-22, which is mediated by glutamate, an inducer of oxidative stress in neurons. Furthermore, it was shown that linalool attenuates oxidative stress and mitochondrial dysfunction mediated by glutamate and N-methyl-D-aspartic acid (NMDA) toxicity, proposing its role as a neuroprotective agent against neurodegenerative brain diseases where oxidative stress contributes to their pathology. In the case of p-cymene, its antioxidant potential has been evaluated in the hippocampus of mice that were intraperitoneally treated with 0.05% Tween 80. p-Cymene significantly decreased lipid peroxidation and nitrite content, whereas significantly increased SOD and catalase activity, proposing its use as an in vivo antioxidant compound as well as a neuroprotective agent in the brain.

In contrast to their protective effects on oxidative stress, treatment of some terpenes may cause oxidative stress. Camphor is a monoterpene widely used in cosmetics, pharmaceutics, and the food industry. Agus et al. have demonstrated that it induces oxidative stress-mediated apoptotic cell death in a unicellular eukaryotic model, the fission yeast Schizosaccharomyces pombe. In that study, camphor-induced excessive ROS production caused a dramatic increase in mortality rates due to the induction of intrinsic apoptosis revealed by mitochondrial impairment and apoptotic nuclear morphology, alerting the potential effects of camphor on apoptotic cell death. On the other hand, α-phellandrene that is widely used in the food and perfume industry has been reported to induce cell morphological changes and apoptosis in vitro in murine leukemia WEHI-3 cells. Treatment with α-phellandrene-induced ROS production and cytochrome c release from mitochondria, subsequently triggering apoptosis of the tumor cells, thus suggesting its potential as an anti-tumor agent. However, interestingly, an opposite activity of α-phellandrene on wound healing has recently been reported, as it was shown to attenuate inflammation and oxidative stress in vitro.

2.5. Autophagy

Through autophagy, cells can eliminate damaged or harmful components, thus, allowing the cells to survive when responding to multiple stressors. There is increasing evidence suggesting that autophagy plays a critical role in the development and pathogenesis of inflammation and immunity response.

Limonene has been shown to strongly stimulate autophagy and to prevent tumor growth in vivo as well as in vitro. The treatment of limonene accelerates LC3 lipidation, which is accomplished by targeting autophagosome formation and induction of basal autophagy via activating ERK and by not inhibiting the mTOR kinase. Russo et al. demonstrated that limonene increases the levels of LC3-II, a lipidated form of LC3, and subsequently stimulates autophagy to induce cell death and decrease the viability of neuroblastoma cells. Another monoterpene, camphor have also been studied about its effects on autophagy in yeast Schizosaccharomyces pombe. In this study, low-dose camphor exposure activated autophagy, confirmed by increased autophagic vesicles and transcriptional upregulation of autophagy-related gene 6 (Atg6), whereas high-dose camphor exposure resulted in dramatic cell death rates. Among yeast apoptosis mediators, allograft inflammatory factor 1 (Aif1) was found to mediate camphor-induced cell death, indicating differential regulation of autophagy and apoptosis depending on the camphor dose.

Several interesting cases of terpene usage for the development of anti-tumor drug candidates related to autophagy activities have been reported. Borneol promotes autophagy by enhancing the permeability of chemicals, especially to brain. In one study, Yu et al. have investigated the effect of the treatment with the combination of tetramethylpyrazine phosphate (TMPP) and borneol on the alleviation of ischemia/reperfusion (I/R) injury. The combination therapy synergistically enhanced autophagy via increasing the levels of LC3-II/I, phosphorylated pAMPK and ULK1 to protect the hypothalamus and striatum against I/R-induced apoptosis. In another study, Yu et al. have examined the effect of TMPP and borneol on the I/R-induced damage in the cortex and hippocampus. This combination therapy increased the levels of pAMPK and ULK1, while it decreased mTOR to switch from apoptosis to protective autophagy. On the other hand, p-cymene can be utilized to synthesize novel and efficient metal anti-tumor drugs, ruthenium complexes. These complexes displayed lack of cytotoxicity in vivo as well as in vitro, and successfully exhibited anti-proliferative capacity associated with a combined mechanism of apoptosis and autophagy.

2.6. Functions of Terpenes on Other Pathways

Recently, many novel action mechanisms of volatile terpene compounds have been reported on their anti-inflammatory functions. For example, limonene treatment reduced methylglyoxal-triggered ER stress that induces inflammatory signaling in the murine preosteoblast cell line, in addition to its autophagic and ROS releasing activities. In addition, α-pinene was shown to induce cell cycle arrest and anti-tumor activity by controlling miR-221, expending their functions on microRNA regulation. Moreover, 3-carene as well as α-pinene were shown to function as positive modulators for benzodiazepine (BZD)-receptors, exerting a sleep-enhancing effect upon oral administration, supporting the beneficial effects of forest bathing for patients with sleep disorders or anxiety.

Recent studies have also focused on novel mechanisms associated with the activity of volatile terpene compounds on vascular- or neuroinflammation. Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-dependent transcription factor that inhibits the expression of inflammatory cytokines and directs the differentiation of immune cells toward anti-inflammatory phenotypes. Thus, natural PPARγ agonists found in foods may be beneficial to human health by acting as anti-inflammatory molecules. In an experiment involving diet-induced dyslipidemia and vascular inflammation with Wistar rats, β-caryophyllene induced the suppression of vascular inflammation via the PPARγ receptor, a treatment superior to pioglitazone, an approved PPARγ agonist. As for action against neuroinflammation, Cutillas et al. demonstrated that some terpene components from Spanish marjoram suppress both lipoxygenase and acetylcholinesterase activities, among which bornyl acetate and limonene showed the highest lipoxygenase inhibition, while 1,8-cineole was the best acetylcholinesterase inhibitor. 5-Lipoxygenase is a pro-inflammatory enzyme; acetylcholinesterase inhibitors were also shown to reduce the pro-inflammatory response as well as post-surgery neurodegeneration in the cortex and hippocampus. Thus, terpene components are suggested as topics for further research into inflammatory and Alzheimer’s diseases.

3. Therapeutic Potentials of Volatile Forest Terpene and Terpenoids on Inflammatory Diseases: Respiratory Inflammation, Atopic Dermatitis, Arthritis, and Neuroinflammation

Currently, many therapeutic chemicals have been developed to treat inflammation, some of which induce severe side effects. Thus, the search of novel anti-inflammatory agents with fewer side effects is highly appealing. Terpene products in various forms have been used as ethnomedicines for a long time due to their beneficial healthcare effects. Individual treatment with terpene compounds as well as a number of essential oils containing monoterpenes from plants have been reported to exert anti-inflammatory activities by inhibiting various proinflammatory steps, as described above, suggesting their application potential as therapeutic agents against many inflammatory diseases. In this section, we focus on therapeutic potentials of volatile terpenes and terpenoids emitted in forested areas, which have been reported so far to be associated with four inflammatory diseases; respiratory inflammation, atopic dermatitis, asthma, and neuroinflammation. According to literature search, 12 compounds among the major types of terpene compounds emitted in forested areas have been reported to be effective in the four diseases; six terpenes (α-pinene, β-pinene, d-limonene, myrcene, α-terpinene, and β-caryophyllene) and six terpenoids (1,8 cineole, camphor, borneol, α-terpineol, linalool, and bornyl acetate).

3.1. Respiratory Inflammation

Asthma is a chronic respiratory condition that results in inflammation and constriction of the bronchiole airways. Despite incomplete understanding, asthma has been known to be caused by a combination of complex interactions between environmental and genetic factors. Environmental factors include exposure to air pollution and allergens, while many different genes have been implicated as risk factors for asthma. Studies on six or more separate populations revealed that asthma is associated with various genes, such as CTLA4, GSTM1, IL4R, IL10, LTC4S, and SPINK5, many of which are related to the immune system or inflammation. Although symptoms can be prevented by avoiding allergens and irritants, and by the use of inhaled corticosteroids, there is no cure for asthma.

Several studies have shown the beneficial effects of some volatile terpene compounds via the anti-inflammation response on airway inflammation in animal models of allergic asthma. In the mouse asthma model, inhalation of limonene significantly reduced the levels of various proinflammation-related molecules as well as airway fibrosis, indicating that limonene has the potential to reduce airway remodeling. Further in vivo investigation using an asthmatic rat model, a novel series of α-terpineol derivatives improved lung function as well as enhanced airway smooth muscle relaxation activity. In addition, borneol and terpineol, extracted from a traditional Chinese formulation for the treatment of asthma, inhibited histamine-induced in vitro bronchoconstriction of isolated tracheal smooth muscles in guinea pigs, thus, indicating anti-asthmatic action.

Positive effects of volatile terpene compounds on asthma have been demonstrated in human studies as well. α-Pinene was shown as a bronchodilator in human volunteers at low exposure levels, making it of value to patients with asthma. Another example is 1,8-cineole. Based on its pharmacodynamic effects proven in numerous pre-clinical studies, 1,8-cineole has been shown to have clinical efficacy and therapeutic benefits in inflammatory airway diseases, such as asthma and chronic obstructive pulmonary disease in a placebo-controlled, double-blind trial.

In contrast to asthma, pneumonia is a lung infection caused by bacteria, fungi, parasites, or viruses. Like asthma, pneumonia causes lung inflammation, but, at the end, it affects the alveoli at the end of the bronchiole airways. Pneumonia can cause the lungs to fill with mucus, making breathing difficult, but it is curable. A positive effect of bornyl acetate treatment on lung inflammation has been reported in a mouse model with acute lung injury. To induce acute lung injury, BALB/c mice were injected intranasally with LPS. Pretreatment with bornyl acetate downregulated the levels of proinflammatory cytokines as well as the phosphorylation of various signaling molecules related to inflammation. The bornyl acetate treatment reduced the total number of cells, neutrophils, and macrophages, and reduced histologic alterations in the lung, suggesting bornyl acetate as a preventive agent for lung inflammatory diseases.

Another condition of airway inflammation is allergic rhinitis, which is a disorder of the upper airways caused by an inflammation of the nasal membranes. Asthma and allergic rhinitis often coexist, with allergic rhinitis being a major risk factor for the occurrence of asthma. For the application of terpenes on allergic rhinitis the therapeutic usefulness of α-pinene was suggested. α-pinene was administered daily to mice before intranasal OVA challenge. Pretreatment with α-pinene caused a decrease in clinical symptoms. In addition, the levels of various proinflammatory mediators such as TNF-α and MIP-2, and nasal IgE declined in OVA-sensitized mice, suggesting α-pinene as a promising anti-allergic agent for the clinical management of allergic rhinitis.

In contrast to the beneficial effects described above, adverse effects of inhaled terpene compounds on airways can also be found. Oxidation products of α-pinene and d-limonene have been shown to cause irritation both in the upper airways and pulmonary regions in mice. In addition, results from a population-based cross-sectional survey of the association between VOCs in residential indoor air and lung function in Canada revealed α-pinene was one among 10 chemicals that were negatively associated with lung function out of 84 VOCs examined.

3.2. Atopic Dermatitis

Atopic dermatitis (AD) is a common chronic inflammatory skin disease. Genetic susceptibility plays an important role in causing atopic dermatitis, for example, defects in skin genes important for maintaining the barrier function. Cytokines are another trigger of AD, which are involved in the negative regulation of immunopathogenesis of AD. Mouse models for AD can be categorized into three groups, among which is NC mouse that spontaneously develops AD-like skin lesions. Several sublines of NC mice including NC/Nga, NC/Jic, and NC/Tnd, have been developed. Upon topical application of β-pinene, atopic-like skin conditions in NC/Tnd mice were ameliorated. In the atopic dermatitis mouse model induced by 2,4-dinitrochlorobenzene, as well as in an in vitro experiment with a human adult low-calcium high-temperature keratinocytes, Cinnamomum camphora leaves, whose major component is camphor, alleviated atopic dermatitis symptoms and allergic skin inflammatory responses, such as inhibition of chemokine production as well as Jak/STAT and ERK 1/2 phosphorylation. The inhibitory effects of BVOCs such as borneol and myrcene on AD were also demonstrated in vitro. Borneol showed strong inhibitory effects on the human transient receptor potential cation channel, member A1 (hTRPA1), possibly due to its blocking action on TRPA1, expressed in sensory neurons, which functioned as a TRPA1 antagonist with anti-inflammatory and anti-allergic effects. Myrcene ameliorates human skin aging via upregulation of MMPs production and downregulation of MAPK-related signaling molecules such as pERK, pp38, and pJNK and AP-1.

However, in addition to the beneficial effects of the above volatile terpene compounds on AD, many adverse cases have also been reported. In evaluation studies using various assays, many compounds including α-pinene, β-pinene, limonene, beta-phellandrene, and camphor, have been reported to show positive allergenicity responses causing contact dermatitis. Despite their beneficial activities as antioxidants, some volatile terpene compounds can autoxidize rapidly to skin allergens on air exposure. Previous studies have shown that though limonene, linalool, caryophyllene, α-terpinene are not allergenic themselves, they readily form allergenic compounds on air-exposure; and there were patients that showed a positive reaction to the oxidized products, emphasizing the need of testing with such compounds.

3.3. Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that is characterized by progressive destruction of articular cartilage and bone and is difficult to treat effectively. Although genetic and environmental factors have been reported to be involved in the development of RA, the pathogenesis of RA has not yet been completely understood because of its complex and multifactorial etiology. Recently, accumulating data have shown the potential role of epigenetic mechanisms in the development of RA. Although there has been significant progress toward achieving disease remission without joint deformity with the aid of anti-rheumatic drugs and pharmacologic therapies, a considerable proportion of RA patients do not effectively respond to the current therapies and thus new drugs are urgently required.

One of the most common experimental models for an RA study is adjuvant-induced arthritis using rats, where a strong and generalized inflammatory response is exhibited. This animal model allows researchers to investigate the pathogenesis in the joints as well as systemically, such as modifications in liver metabolism, which share features of RA seen in patients. Among the 23 volatile terpene compounds investigated in this study, β-caryophyllene has been reported as a good candidate to treat RA. Vijayalaxmi et al. evaluated the ameliorative effect of oral administration of β-caryophyllene in rats with experimental arthritis induced by Complete Freund’s adjuvant, and found that the compound significantly decreased arthritis and improved arthritis index, paw volume as well as histopathology and biochemical parameters such as anti-oxidants and serum nitrates. More recently, β-caryophyllene has been found to reduce systemic inflammation in rats with adjuvant-induced arthritis and to, additionally, reduce oxidative stress in the liver and plasma of these animals without hepatotoxicity, suggesting β-caryophyllene as a starting point for the development of novel anti-inflammatory drugs.

In contrast to RA, osteoarthritis (OA) is a degenerative disorder including mild inflammation. Rufino et al. demonstrated the anti-inflammatory and chondroprotective effect of α-pinene in human chondrocyte, in which α-pinene prevented against IL-1β-stimulated inflammatory and catabolic pathways, such as NF-κB and JNK activation and the expression of the inflammatory (iNOS) and catabolic (MMP-1 and -13) genes this suggests potential value as an anti-osteoarthritic drug. In addition, Bornyl acetate is the main volatile constituent in some Chinese traditional herbs, and Yang et al. reported its therapeutic potential in patients with OA. In the study, they found that bornyl acetate elevates the expression of IL-11 in chondrocytes, and functions antagonistically on IL-1β-mediated up-regulation of IL-6, IL-8, MMP-1, and MMP-13, which play a pivotal role in OA cartilage destruction.

3.4. Neuroinflammation

Neuroinflammation is inflammation in the nervous tissue and is mainly mediated by microglia, the resident mononuclear phagocytes of the brain. Activation by various pro-inflammatory cues, including invading pathogens, trauma, infection, and stroke, triggers neuroinflammatory responses including activation of microglia, local invasion of circulating immune cells, and production of inflammatory factors. Expression of receptors for sensing potential threats and microglial pro-inflammatory cytokines, as well as production of ROS and NO, are increased in the activated microglia. Although an acute inflammatory response is beneficial to neurons, chronic inflammation damages the brain; therefore, abnormal activation of neuroinflammatory processes has been implicated in neurodegenerative diseases and brain injuries.

Coincident with their anti-inflammatory activity in the peripheral macrophages, some terpenes have been shown to inhibit the activation of microglia under several pro-inflammatory cues in in vitro studies (Table 2). For example, β-caryophyllene inhibited release of pro-inflammatory cytokines and production of NO and PGE2 as well as the activation of NF-κB in the cultured microglia cells under hypoxia or Aβ-treatment. Anti-neuroinflammatory activity of linalool, β-caryophyllene and borneol was also observed in the LPS-stimulated microglia cells. On the other hand, eucalyptol and borneol have shown to exert their inhibitory effects on the pro-inflammatory responses in Aβ-treated PC12 cells and rat primary cultured cortical neurons with oxygen-glucose deprivation, respectively. Based on the fact that β-caryophyllene is a ligand of CB2R that is closely related with neuroinflammation, most in vivo studies focused on the effect of β-caryophyllene on neuroinflammation. β-Caryophyllene inhibited neuroinflammation and showed beneficial effects in models of insulin resistance and obesity, Parkinson’s disease, and multiple sclerosis. Additionally, borneol attenuated brain neuronal and microglial inflammation in LPS-induced sepsis mice, and d-limonene reduced glial cell number and NO levels in the brain of Drosophila model of Alzheimer’s disease.

Despite their anti-inflammatory activity in the peripheral macrophages, only a limited number of studies have shown the suppressive function of some volatile terpenes and terpenoids against neuroinflammation. However, given that many studies showed the neuroprotective properties of these compounds, more terpenes are expected to have neuroinflammatory activity. Therefore, further research is required in the future.

4. Conclusions

There has been an increase in the search of terpenes with anti-inflammatory activity in recent years. As summarized in this review, the mechanisms involved in the anti-inflammatory effects of the terpenes contained in BVOCs emitted in forests cover a wide range of targets such as transcription factors and inflammatory mediators. Although the mechanism of action of many terpenes remains to be studied, the molecular targets of terpenes are highly desirable for finding target-specific anti-inflammatory drugs. The combination of terpenes with high anti-inflammatory activity and with studied mechanisms of action, with currently used drugs could be another strategy to combat inflammatory diseases.

As more terpenoid-based clinical drugs will become available, they will play a more significant role in human disease treatment in the near future. However, some adverse effects of terpenes have been reported, depending on the concentrations of the compounds tested. For example, among the compounds described in this review, cytotoxic effects have been demonstrated for α-pinene and camphor. According to the Food and Drug Administration, camphor-containing products cannot exceed 11% camphor. In addition, allergic contact dermatitis has been reported following the use of α-pinene, β-pinene, and myrcene. This issue draws attention on the need to further explore the safe concentrations of terpenes for therapeutic proposes. In this context, contact of BVOCs during forest bathing may be safer, albeit less beneficial compared to direct intake or application on skin. Taken together, this review highlights the use of the beneficial terpenes and terpenoids from forests for the management of various inflammatory-related diseases.

References 193

  1. 1.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  2. 2.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  3. 3.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  4. 4.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  5. 5.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  6. 6.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  7. 7.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  8. 8.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  9. 9.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  26. 26.
  27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  34. 34.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  41. 41.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  42. 42.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  43. 43.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  44. 44.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  45. 45.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  46. 46.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  47. 47.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  48. 48.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  49. 49.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  50. 50.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  51. 51.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  52. 52.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  53. 53.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  54. 54.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  55. 55.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  56. 56.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  57. 57.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  58. 58.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  59. 59.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  60. 60.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  61. 61.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  62. 62.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  63. 63.
  64. 64.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  65. 65.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  66. 66.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  67. 67.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  68. 68.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  69. 69.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  70. 70.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  71. 71.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  72. 72.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  73. 73.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  74. 74.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  75. 75.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  76. 76.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  77. 77.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  78. 78.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  79. 79.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  80. 80.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  81. 81.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  82. 82.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  83. 83.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  84. 84.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  85. 85.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  86. 86.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  87. 87.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  88. 88.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  89. 89.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  90. 90.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  91. 91.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  92. 92.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  93. 93.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  94. 94.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  95. 95.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  96. 96.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  97. 97.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  98. 98.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  99. 99.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  100. 100.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  101. 101.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  102. 102.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  103. 103.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  104. 104.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  105. 105.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  106. 106.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  107. 107.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  108. 108.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  109. 109.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  110. 110.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  111. 111.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  112. 112.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  113. 113.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  114. 114.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  115. 115.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  116. 116.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  117. 117.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  118. 118.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  119. 119.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  120. 120.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  121. 121.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  122. 122.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  123. 123.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  124. 124.
  125. 125.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  126. 126.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  127. 127.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  128. 128.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  129. 129.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  130. 130.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  131. 131.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  132. 132.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  133. 133.
  134. 134.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  135. 135.
  136. 136.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  137. 137.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  138. 138.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  139. 139.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  140. 140.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  141. 141.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  142. 142.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  143. 143.
  144. 144.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  145. 145.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  146. 146.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  147. 147.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  148. 148.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  149. 149.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  150. 150.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  151. 151.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  152. 152.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  153. 153.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  154. 154.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  155. 155.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  156. 156.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  157. 157.
  158. 158.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  159. 159.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  160. 160.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  161. 161.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  162. 162.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  163. 163.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  164. 164.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  165. 165.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  166. 166.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  167. 167.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  168. 168.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  169. 169.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  170. 170.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  171. 171.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  172. 172.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  173. 173.
  174. 174.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  175. 175.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  176. 176.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  177. 177.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  178. 178.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  179. 179.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  180. 180.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  181. 181.
  182. 182.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  183. 183.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  184. 184.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  185. 185.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  186. 186.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  187. 187.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  188. 188.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  189. 189.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  190. 190.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  191. 191.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  192. 192.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  193. 193.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.